Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
This grant funds further development and validation of new molecular and cellular analysis technologies to improve basic and clinical cancer research, excluding projects using existing technologies for new targets.
Funder: National Institutes of Health
Due Dates: April 10, 2026 (Estimated application due date) | November 10, 2026 (Application closing date)
Funding Amounts: Up to $300,000 per award; estimated total program funding $5,900,000; ~13 awards expected.
Summary: Supports further development and validation of emerging technologies for molecular or cellular characterization of cancer or improved biospecimen handling in basic and clinical cancer research.
Description
This opportunity from the National Cancer Institute (NCI) invites applications for exploratory research projects focused on the advanced development and rigorous technical validation of emerging technologies that offer new capabilities for the molecular or cellular characterization of cancer, or for improved handling and quality control of biospecimens used in cancer research. The goal is to encourage the adoption of innovative technologies that can accelerate or enhance research in cancer biology, early detection, screening, diagnosis, treatment, epidemiology, and cancer control. Projects must demonstrate that major feasibility gaps have already been overcome with supportive preliminary data, but require further development and validation. Proposals must focus on cancer-relevant use cases. Applications that simply apply existing technologies to novel biological or clinical questions, where the innovation is not in the technology itself, are not responsive.
This NOFO is part of the broader NCI Innovative Molecular Analysis Technologies (IMAT) Program.
